PreveCeutical Announces Filing of Preliminary Prospectus for Initial Public Offering and Private Placement

VANCOUVER, British Columbia, Oct. 05, 2016 (GLOBE NEWSWIRE) — PreveCeutical Medical Inc. (“PreveCeutical“, or the “Company“), a health and wellness company focused on utilizing nature and science for the benefit of health-conscious consumers, has filed and obtained a receipt for its preliminary non-offering prospectus with the British Columbia Securities Commission (the “BCSC”). The preliminary prospectus contains important information relating to the Company and its currently issued securities and is subject to amendment as may be required by the BCSC. Copies of the preliminary prospectus are available on SEDAR at

The Company is currently undertaking a non-brokered private placement for up to $5,000,000 CAD priced at $0.50 CAD per common share (the “Offering“), which is intended to be the Company’s final offering prior to the planned listing of its common shares on the Canadian Securities Exchange (the “CSE”). The Company is preparing for its listing application to the CSE. Completion of the Offering is subject to, and conditional upon, the receipt of all necessary approvals, including regulatory approvals, if any and as applicable. The Offering is expected to close in late October or early November 2016 in the Company’s discretion and prior to the submission of a final non-offering prospectus to the BCSC.

Consistent with its strategy announced in December 2015, PreveCeutical was established to provide investors with the opportunity to invest directly into a health and wellness platform, which includes the first go-to-market product CELLB9TM.

On Behalf of the Board,

“Stephen Van Deventer”
Chairman & CEO

About PreveCeutical

The Board of Directors of PreveCeutical is led by Mr. Stephen Van Deventer, as Chairman, and includes Ms. Kimberly Van Deventer, Mr. Jeremy Wright, CPA, CMA, Mr. Brian Harris, Mr. Greg S. Reid, and Mr. Alex Bayer. The executive management team of PreveCeutical is led by Mr. Stephen Van Deventer as Chief Executive Officer, and includes: Ms. Kimberly Van Deventer as President; Ms. Shabira Rajan, CPA, CGA as Chief Financial Officer, Dr. Makarand Jawadeker PhD as Chief Science Officer, Ms. Nicole Goncalves-Krysinski as Chief Legal Officer, Mr. Brian Harris as Vice President of Corporate Development, and Ms. Alicia Rebman as Vice President of Marketing and Advertising.

For more information about PreveCeutical, please visit, follow us on Twitter:, or on Facebook:

No U.S. Offering or Registration

The securities of PreveCeutical have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities laws. Accordingly, these securities may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or except pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of PreveCeutical’s securities in the United States.

Forward Looking Information

This news release may contain forward-looking statements, including without limitation, future operations of PreveCeutical Medical Inc. (the “Company“). Forward-looking statements address future events and conditions and therefore involve inherent risks, uncertainties and assumptions. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “will”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations.  Actual results may differ materially from those currently anticipated in such statements and the Company undertakes no obligation to update such statements, except as required by law.  While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. In particular, there is no guarantee that: (1) the CELLB9TM will be marketed, marketed as planned, or a successful product offering if ever marketed; (2) the Offering will close or raise sufficient funds for the Company in order to continue and/or expand operations; (3) the Company will be able to raise up to the stated amount of the Offering or that the Offering will be the final offering of the Company’s securities prior to its intended listing; (4) a final prospectus will be submitted and/or a receipt for the final prospectus will be obtained; and (5) the intended listing with the CSE would be successful. Accordingly actual results may differ materially from those currently anticipated in such statements.

The Company has made numerous assumptions regarding, among other things: the effectiveness of its products; the demand for its products and the stability of economic and market conditions. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including: that the Company may lose or abandon or may fail to receive necessary licenses and permits; labour disputes; the Company may not receive the necessary regulatory approvals for its products or the listing with the CSE or approvals with respect to the prospectus; the increase in cost estimates and the potential for unexpected costs and expenses; general economic and market conditions may worsen; market shifts may require a change in strategic focus; the Company may not be able to raise additional funds when necessary; litigation; and competition. Factors that could cause actual results to differ materially from those in forward looking statements include continued availability of capital and financing and general economic, market or business conditions, consumer sentiment towards the Company’s products, competition, the failure of counterparties to perform their contractual obligations, and fees charged by service providers.

All forward-looking statements concerning the Company’s future plans and operations, including management’s assessment of the Company’s operational expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company’s control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and financial results may differ materially from any estimates or projections. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward looking information, will prove to be accurate.

CONTACT: PreveCeutical Medical Inc.
Suite 605 – 815 Hornby Street,
Vancouver, B.C., V6Z 2E6, Canada
1 (866) 398-1288
Logo Header Menu